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Abstract
Background: Galectin-9 is a mammalian lectin which possesses immunosuppressive properties. Excessive
production of galectin-9 has been reported in two types of human virus-associated diseases chronic hepatitis C and
nasopharyngeal carcinoma associated to the Epstein-Barr virus. The objective of this study was to produce new
monoclonal antibodies targeting galectin-9 in order to improve its detection in clinical samples, especially on tissue
sections analysed by immunohistochemistry.
Methods: Hybridomas were produced through immunization of mice with the recombinant c-terminus part of
galectin-9 (residues 191 to 355 of the long isoform) and semi-solid fusion of spleen cells with Sp2/0 cells.
Monoclonal antibodies were characterized using ELISA, epitope mapping, western blot and immunohistochemistry.
Results: We selected seven hybridomas producing antibodies reacting with our recombinant c-terminus galectin-9
in ELISA. Five of them reacted with the epitope “TPAIPPMMYPHPA” (common to all isoforms, residues 210 to 222 of
the long isoform) and stained all three isoforms of galectin-9 analysed by western blot. One of them, 1G3,
demonstrated very good sensitivity and specificity when used for immunohistochemistry. Using 1G3, we could
confirm the intense and constant expression of galectin-9 by Epstein-Barr virus positive malignant cells from
nasopharyngeal carcinomas. In most samples, specific staining was detected in both cytoplasm and nuclei. Galectin-9
was also detected in liver biopsies from patients infected by the human hepatitis C or B viruses with expression not
only in inflammatory leucocytes and Kupffer cells, but also in hepatocytes. In contrast, galectin-9 was virtually absent in
non-infected liver specimens.
Conclusion: The 1G3 monoclonal antibody will be a powerful tool to assess galectin-9 expression and distribution
especially in diseases related to oncogenic viruses.
Background
Galectin-9 is a β-galactoside binding lectin of mamma-
lian origin which possesses two distinct carbohydrates
domains linked together by a peptide sequence of 14, 26
or 58 aminoacids depending on the isoform, respectively
S, M or L isoform. Galectin-9 holds multiple immuno-
modulatory properties and an overall predominantly im-
munosuppressive function. In the context of murine
immunity, galectin-9 has been shown to play a key role
in a regulatory feed-back essential for a physiological
termination of the Th1 immune response [1]. CD4+
Th1 lymphocytes produce interferon-gamma which
induces galectin-9 production by various cell types
including fibroblasts and endothelial cells. Conversely,
galectin-9 induces inhibition of CD4+ Th1 lympho-
cytes, at least in part through stimulation of the Tim-3
receptor. It also induces expansion of regulatory T-cells
in mice [2,3]. Recent studies performed in murine sys-
tems have provided novel insights about its immunosup-
pressive functions in the context of viral infections. In
mice infected by the herpes simplex virus 1 (HSV1),
galectin-9 induces apoptosis of CD4+ Th1 and CD8+
T-lymphocytes [4,5]. Interestingly these immunosup-
pressive effects have both adverse and beneficial effects
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regarding the pathological consequences of HSV1 infec-
tion. Galectin-9 favors HSV1 reactivation in the trigem-
inal nerve whereas it limits the extent of corneal lesions
and neovascularisation in murine experimental herpetic
keratitis. Galectin-9 also decreases the intensity of
humoral and cellular immune response to RNA viruses
like the influenza A virus in another murine experimen-
tal system [6].
Although recent data obtained in mouse experimental
systems keep bringing new elements concerning the im-
munosuppressive and regulatory function of galectin-9,
the physiological and pathological role of galectin-9 in
humans remains poorly documented and controversial.
There is evidence that alterations of galectin-9 functions
could contribute to auto-immune diseases. For example,
the Tim-3 receptor on CD4+ Th1 clones from patients
with multiple sclerosis (MS) is defective in its response
to galectin-9 [7,8]. Similar results were reported for
patients with rheumatoid arthritis and recently auto-
immune hepatitis [9,10]. Reciprocally, there is evidence
of excessive galectin-9 production in two human dis-
eases associated with oncogenic viruses : nasopharyngeal
carcinomas (NPC) associated with the Epstein-Barr virus
(EBV) and chronic infection by the hepatitis C virus
(HCV) [11,12]. Indeed, recent works have shown the
presence of tumor exosomes carrying galectin-9 in the
blood of NPC patients. In vitro, NPC exosomes have a
direct deleterious effect on several human CD4+ T-cell
clones specific of EBV-antigens [11]. Using an ELISA
test, we have detected unusually high concentrations of
galectin-9 in the blood of patients with chronic hepatitis
C, especially those HCV-related hepatocellular carcin-
omas [12]. It seems that in this context, galectin-9 is
produced mainly by Kupffer cells. The same report
demonstrates that in vitro recombinant galectin-9
induces expansion of regulatory T cells and apoptosis of
HCV-specific cytotoxic T cells whereas it increases the
production of pro-inflammatory cytokines from mono-
nuclear cells [12]. Thus, galectin-9 may be a key element
in regulating T cell response in the liver and thus in the
establishment of viral persistence.
Despite the growing number of studies being published
on galectin-9, no monoclonal antibody (mab) has yet been
recommended for immunohistochemistry. To our know-
ledge, in previous publications, immunohistochemistry of
galectin-9 was only based on polyclonal antibodies [13].
Therefore we have produced a collection of novel anti-
galectin-9 hybridomas and we have selected one of
them – the 1G3 clone - producing a mab highly efficient
for staining of tissue sections. Using this antibody, we
could observe strong staining of malignant epithelial cells
in NPC tissue sections. We could also observe galectin-9
staining of inflammatory leucocytes, Kupffer cells and
hepatocytes in liver biopsies from patients with chronic
viral hepatitisC and B. This antibody is expected to be-
come useful in a wide range of human diseases, especially
those related to oncogenic viruses.
Methods
Production of anti-galectin-9 monoclonal antibodies
The recombinant S and M isoforms of human galectin-9
and the M isoform of murine galectin-9 were produced
in E. coli as GST-fusion proteins. Tag-free proteins were
purified by affinity chromatography on a lactose-agarose
column [17]. The c-terminus galectin-9 (residues 191 to
355 of the galectin-9 long isoform) was produced in E.
coli as a GST-fusion protein. The tag-free protein was
purified by exclusion chromatography. Immunizations
were conducted at PX’Therapeutics (Grenoble, France).
Five BALB/c female mice (eight weeks old) were immu-
nized with the recombinant c-terminus galectin-9.
Immunizations (40 μg of protein) were administered
intraperitoneally at days 0, 22, 37 and 54 with complete
Freund’s adjuvant for the first immunization, then with
incomplete Freund’s adjuvant for subsequent injections.
We performed enzyme-linked immunosorbent assay
(ELISA) on mice serum to confirm response to galectin-9
immunization, using the same recombinant galectin-9
c-terminus part which was injected into mice. A rabbit
polyclonal serum raised against the same portion of
galectin-9 was used a positive control. The five immu-
nized mice exhibited a specific and strong immune re-
sponse against the c-terminus part of galectin-9. Three
days after the last boost, the two best responding mice
were sacrificed and their splenocytes were collected to use
in subsequent liquid or semi-solid fusion with Sp2/0 cells
at a ratio of 5:1 and 2:1 respectively. Hybridomas superna-
tants were assessed in galectin-9 ELISA. The semi-solid
fusion was successful and a large collection of monoclonal
hybridomas secreting anti-galectin-9 antibodies was
obtained.
Galectin-9 ELISA for assessment of mouse sera and
selection of hybridomas
Wells of microtiter plates (Greiner Bio-One, Courtaboeuf,
France) were coated with 0.05 M carbonate/bicarbonate
buffer (Sigma-Aldrich, Saint-Quentin Fallavier, France)
pH 9.6 containing 50 ng human c-terminus galectin-9
during 1 H at room temperature. After washing with phos-
phate buffered saline (PBS) containing 0.1% Tween-20
(Euromedex, Souffelweyersheim, France), the wells were
saturated with 3% bovine serum albumine (BSA) (Sigma-
Aldrich, St Quentin Fallavier, France) in PBS at room
temperature for 1 H. They were then incubated with
mouse sera or raw hybridoma supernatants in PBS with
1% BSA at room temperature for 2 H. After a washing step
with PBS with 0.1% Tween-20, the anti-galectin-9 antibody
level was determined using horseradish peroxidase-coupled
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(HRP) goat antibodies to mouse IgG (Sigma-Aldrich, St
Quentin Fallavier, France) and 3,3’,5,5’ Tetramethylbenzi-
dine (TMB) (Thermo Fisher Scientific, Brebieres, France)
as substrate. Microtiter plates were incubated 15 min in
the dark under shaking before stopping the reaction with
1 M H2SO4. Then, OD was read at 405 nm and 620 nm
using a MultiSkan Ex microplate reader (Thermo Fisher
Scientific). Experiments were performed in duplicates.
ELISA for epitope mapping and oligopeptide competition
A panel of 27 oligopeptides representative of the 168
amino-acids from the c-terminus galectin-9 used for
mice immunisation was produced. Oligopeptides were
13 amino-acids long, with a 7 amino-acids overlap. For
epitope mapping, each peptide was coated in 96-well
plate using 100 ng/well during 16 hours at 4 °C. For
oligopeptide competition, full length galectin-9 (recom-
binant S isoform produced in E. Coli) was coated in the
same conditions. Wells were saturated in PBS + 0.1%
BSA at room temperature during 2 hours, then incu-
bated with purified mouse monoclonal antibodies during
2 hours at room temperature. For oligopeptide competi-
tion, 1G3 was tested in parallel with the mab 9S2-3
which targets the n-terminus of galectin-9 [14]. The anti-
bodies were pre-incubated during 2 H at room temperature
with control oligopeptide (“ITQTVIHTVQSAP”) or target
oligopeptide (“TPAIPPMMYPHPA”) using serial dilutions
ranging from 4 μg/ml to 2 ng/ml. Revelation of bound
monoclonal antibodies was performed using a peroxidase-
conjugated secondary antibody as described in the previous
paragraph.
Capture of biotinylated galectins on surface-bound
antibodies
For this assay, we used the following recombinant galec-
tins: the S and M isoforms of human galectin-9, the
murine M isoform of galectin-9 and human galectin-1,
-2, -3, -4, -8 (M isoform) and −10. Preparation of re-
combinant galectins and their biotinylation have been
already described in previous works [15-17]. 1G3 and
control mouse IgG1 antibody (MOPC21 clone) were
coated in 96-well plates overnight at 4 °C in assay buf-
fer (PBS-Tween, 2% fetal calf serum (FCS), 0.05%
NaN3). Plates were blocked with 5% FCS overnight at
4 °C then washed five times with PBS-Tween. Biotiny-
lated galectins (1 nM) were incubated during 1 H at
37 °C in antibody-coated wells; then plates were
washed five times with PBS-Tween. Revelation of cap-
tured biotynilated galectins was done by addition of
SA-HRP for 1 H at 37 °C. After washing, TMB sub-
strate was added during 2.5 min at room temperature.
Reaction was stopped with 1 M phosphoric acid and
OD was read at 405 nm and 620 nm. Experiments
were performed in duplicates.
Cell lines
BL2 and REMB1 cells were grown in RPMI 1640
medium (Gibco-Invitrogen, Carlsbad, CA) supplemented
with 10% FCS. BL2 is an EBV-negative B-cell line
derived from a Burkitt’s Lymphoma. REMB1 is a lym-
phoblastoid cell line (LCL) resulting from in vitro EBV-
transformation of B lymphocytes from a normal donor.
HeLa cells were cultured in DMEM supplemented with
10% FCS. C15 is an EBV-positive NPC xenograft which
was propagated by subcutaneous passages into nude
mice [11]. C666-1 cells which are EBV-positive NPC
cells were grown in vitro in RPMI 1640 medium supple-
mented with 25 mM HEPES and 7.5% FCS, in plastic
flasks coated with collagen I (Biocoat; Becton-Dickinson,
Franklin Lakes, NJ) [11].
Western blot
Cell pellets were solubilized in RIPA buffer (150 mM
NaCl, 25 mM Tris–HCl pH 7.5, 5 mM EDTA, 0.5% so-
dium deoxycholate, 0.5% NP40, 0.1% SDS) supplemen-
ted with the complete protease inhibitor cocktail (Roche
Applied Science, Neuilly-sur-Seine, France) and soni-
cated on ice. Extracts were clarified by centrifugation for
15 minutes at 16 000 g at 4 °C. Protein concentration
was assayed by the Bradford method using BioRad pro-
tein assay (BioRad, Marnes-la-coquette, France). Cell
protein extracts were separated on 12% polyacrylamide
gels in standard conditions. Gels were blotted on PVDF
membranes (Immobilon-P; Millipore, Molsheim, France)
then blocked during one hour with TBS containing 3%
non-fat milk powder and 4% glycine. Membranes were
incubated overnight with mouse monoclonal antibodies
at the concentration of 2 μg/ml in blocking solution.
Specific protein bands were visualized using goat anti-
mouse HRP–conjugated secondary antibodies and
revealed by chemiluminescence using Immobilon West-
ern kit (Millipore, Molsheim, France).
Clinical specimens
Thirteen samples from head and neck carcinomas were
selected from a retrospective collection of biopsies col-
lected for diagnosis purpose at Lariboisière hospital
(Paris, France). This set of biopsies included ten naso-
pharyngeal carcinomas and three carcinomas of the
oropharynx and oral cavity. Nine liver samples were
selected from a retrospective collection obtained fol-
lowing partial or complete hepatectomy at Beaujon
hospital (Paris, France). This set of surgical samples
included three specimens infected by HCV, three spe-
cimens infected by the hepatitis B virus (HBV) and
three specimens of uninfected patients having under-
gone partial hepatectomy for benign tumors. All these
samples were obtained and processed according to
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guidelines of Lariboisière and Beaujon hospitals institu-
tional review boards.
Immunohistochemistry
Biopsies from head and neck carcinomas and surgical
liver samples were initially fixed in paraformaldehyde 4%
and paraffin-embedded. Prior to galectin-9 staining, tis-
sue sections were dewaxed with xylene and ethanol and
rehydrated. Antigens were unmasked using a pH 6.0 cit-
rate solution at 98 °C during 30 min. After adequate
washing steps, sections were incubated 10 min with 3%
H2O2, washed again and saturated with blocking serum
(Biogenex, MM France, Francheville, France) for 1 hour.
Sections were then incubated with mouse monoclonal
antibodies diluted at 2 μg/ml in blocking serum for 1
hour at room temperature. Visualization was achieved
by exposing sections to a goat anti-mouse HRP 1:50
(Southern Biotech, Clinisciences, Nanterre, France) dur-
ing 30 min at room temperature then adding DAB sub-
strate. The slides were counterstained with Mayer’s
hematoxylin diluted at 1:2 during 1 min at room
temperature.
Results
Preparation and selection of hybridomas
Five mice were immunized with the recombinant c-
terminus portion of galectin-9 (residues 191 to 356 of
the long isoform). Their immune response was moni-
tored by serum ELISA on recombinant c-terminus
galectin-9. As a positive control we used a previously
described rabbit polyclonal serum raised against the
same portion of galectin-9 [11]. Splenocytes were col-
lected from the two best responding mice three days
after the last c-terminus galectin-9 injection. Two
fusions were performed, one with subsequent cloning in
classical conditions (liquid medium in microwell plates)
and the other in semi-solid medium. Only the fusion in
semi-solid medium was successful. A panel of thirty-
nine hybridomas from which culture supernatants were
positive in ELISA screening was obtained. Seven were
selected for their abundant secretion of immunoglobu-
lins and high reactivity with the c-terminus galectin-9 in
ELISA (Figure 1A).
Determination of antibodies epitopes
Monoclonal antibodies produced by the seven selected
hybridomas were subjected to epitope mapping, using a
panel of oligopeptides (P1 to P27) representative of the
168 amino-acids from the c-terminus part of galectin-9.
Five monoclonal antibodies (1G3, 1E12, 2E6, 1F4 and
1D8) were found to recognize the same linear epitope,
with 1G3 consistently having the highest reactivity. The
amino-acid sequence of this preferred epitope is
“TPAIPPMMYPHPA” which corresponds to peptide P4
and covers the end of the linker peptide and the begin-
ning of galectin-9 c-terminus part (Figure 1B). This se-
quence exists in all three isoforms of galectin-9 (aa 166
to 178 in the S-isoform, aa 178 to 190 in the M-isoform,
aa 210 to 222 in the L-isoform) suggesting that those
antibodies can react with all galectin-9 isoforms. Epi-
topes of 2E12 and 2D12 antibodies couldn’t be deter-
mined in this experiment. Therefore these antibodies
may react with a conformational epitope. To confirm
1G3 specificity toward the P4 peptide, a competitive
ELISA was performed using serial dilution of a control
peptide and P4 peptide. 9S2-3 monoclonal antibody,
which targets the n-terminus part of galectin-9, was used
as control antibody [14]. As shown in Figure 1C, only
the peptide P4 was able to reduce 1G3 binding to
galectin-9 S isoform in a concentration-dependent
manner.
Performance in western blot
Protein extracts were prepared from various cell lines
with or without endogenous expression of galectin-9. In
addition, HeLa cells were short-term transfected with
expression plasmids coding for each galectin-9 isoform
(S, M or L). Protein extracts from each cell category
were analysed by western blot using our anti-galectin-9
monoclonal antibodies. All seven antibodies were able to
detect galectin-9 including 2E12 and 2D12 (data not
shown). However, the strongest specific signals were
consistently obtained using the 1G3 monoclonal anti-
body (Figure 2). All three isoforms were detected by
1G3 in HeLa cells transfected with the corresponding
plasmids. A low amount of the S- and M-isoforms were
detected in wild-type HeLa cells. All isoforms were
detected in protein extracts from both C15 and C666-1
NPC xenografts. REMB1 cells (LCL) expressed mainly
the M-isoform and a low amount of the L-isoform, while
no S-isoform could be detected in this experiment. No
galectin-9 was detected in BL2 cells (EBV-negative human
B-cells derived from an EBV-negative Burkitt’s lymphoma)
in agreement with one of our previous report [11].
Determination of 1G3 cross-reactivity
Galectin-9 is a member of a large family of proteins which
share some structural properties and conserved amino-
acids. Therefore, it was important to verify that the 1G3
antibody did not cross-react with other members of the
galectin family. A capture assay was performed using 1G3
or control mouse IgG bound to ELISA plates to assess
their reactivity with biotynilated human galectin-1, -2, -3,
-4, -8 (M isoform) and galectin-10. The M isoform of
murine galectin-9 was also included in this experiment.
Recombinant human galectin-9 isoforms S and M were
used as positive controls. According to the data shown in
Figure 3, 1G3 captures the S and M isoforms of human
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Figure 1 Selection of anti-galectin 9 hybridomas and epitope mapping of the corresponding monoclonal antibodies. A) Seven
hybridomas were selected for their performance in ELISA against recombinant c-terminus galectin-9 (2E12, 1E12, 2E6, 1F4, 1G3, 1D8, 2D12). Their
crude supernatants gave about the same reactivity as the undiluted mouse serum sample taken prior to spleen collection (mouse polyclonal).
Other hybridomas such as 1H12 and 2F4 were set aside due to their lower reactivity with c-terminus galectin-9 in ELISA. B) Mapping of the 1G3
epitope (TPAIPPMMYPHPA) contained in the three natural isoforms of galectin-9. This epitope is close to the n-terminus extremity of the
recombinant c-terminus galectin-9 used for mouse immunization. C) Selective inhibition of 1G3 binding to the recombinant S-isoform of human
galectin-9 by the P4 oligopeptide (TPAIPPMMYPHPA). Plates were coated with human galectin-9 S. Subsequent binding of the mabs 1G3 and
9S2-3 were done after pre-incubation with the P4 peptide or a control peptide. The binding of 1G3 to the galectin-9 is selectively inhibited by
the P4 peptide at concentrations above 0.5 μg/ml. In constrast the binding of 9S2-3 is not affected.
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galectin-9 as well as the murine galectine-9. In contrast, it
does not cross-react with other human galectins.
Performance of 1G3 monoclonal antibody in
immunohistochemistry
The seven mabs were assessed on paraffin-embedded
cell pellets, using BL2 and REMB1 cells as negative and
positive references, respectively. Again the 1G3 antibody
was the most efficient antibody with the best signal/
background ratio. It was selected for subsequent investiga-
tion of galectin-9 expression in various tissue specimens.
As shown on Figure 4 and Table 1, galectin-9 expression
was detected in malignant cells from all ten NPC speci-
mens. It was consistently strong and homogeneous
through the malignant cell population. Cytoplasmic stain-
ing was constant, coexisting in all but one case with nu-
clear staining in at least a fraction of the cells. Weaker
scattered staining of stromal leucocytes was detected in
six of ten cases. Tissue sections from three specimens of
squamous cell carcinomas (SCC) of the oropharynx and
oral cavity were also stained with 1G3 (Figure 4 and
Table 1). In one of them, a tonsil SCC containing a strong
lymphoid infiltrate, substantial galectin-9 staining was
seen in malignant cells. In contrast, malignant cells were
completely negative in tissue sections from other SCCs.
For nine of these head and neck carcinoma specimens
(NPC and non-NPC), fragments of non-malignant epithe-
lium could be observed. In two cases, the epithelium was of
the secretory type including one specimen with positive
staining in about one third of the epithelial cells. In the
seven other specimens, the epithelium was of the pluristra-
tified Malpighian type with absence of galectin-9 staining in
all but one case.
Finally, the 1G3 monoclonal antibody was tested on
nine liver tissue samples infected by HCV or HBV or
uninfected (Figure 5 and Table 2). Galectin-9 was con-
sistently detected in sections from infected but not from
uninfected liver specimens. At a low magnification (X10,
Figure 2 Western blot detection of galectin-9 isoforms using
the 1G3 monoclonal antibody. A low amount of S and M galectin-9
isoforms are present in wild-type HeLa cells. These isoforms are readily
detected following transfection with the appropriate expression
plasmids. The L-isoform is expressed at a lower abundance than the
two other forms. The three endogenous isoforms are detected in the
protein extracts from the C15 and C666-1 NPC xenografts. The EBV-
positive B-cell line REMB1 expresses a high amount of the M-isoform
and a very low amount of L-isoform, however no S-isoform could be
detected. In contrast with REMB1 cells, the BL2 cells derived from an
EBV-negative B-cell lymphoma have no detectable galectin-9. The faint
background bands visible after long exposure do not match with any
galectin-9 isoform.
Figure 3 Demonstration of the specificity of 1G3 binding to galectin-9 by a capture ELISA assay. 1G3 and irrelevant mouse IgG were
adsorbed on an ELISA plate and then incubated with various types of biotynilated human galectins (hGAL 1,2,3,4,7,8 and hG9 and hG10) or the
M-isoform of murine galectin-mG9. Both human and murine galectin-9 are captured by 1G3 in contrast with other galectins which do not exhibit
significant binding to 1G3.
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X50 or X100), galectin-9 was not visible in hepatocytes.
However it was visible in scattered polymorphic cells
suggestive of inflammatory leucocytes and Kupffer cells.
Restricted intense staining of cells with a morphology
typical of Kupffer cells was observed in one case (patient
#2) consistent with our previous report [12]. Scattered
positive cells were also seen in all three specimens
infected by HBV; it was not restricted to Kupffer cells
but was seen in cells of various morphology probably
various types of leucocytes. One additional, unexpected
finding was made at a high magnification (X400). Deli-
cate, punctate staining was visible in a large proportion
of the hepatocytes in all six virus-infected liver samples.
This punctate staining was almost identical for speci-
mens infected by HCV or HBV. However it was not vis-
ible in sections from non-infected liver samples.
Figure 4 Detection of galectin-9 in tissue sections from nasopharyngeal carcinomas and other head and neck carcinomas. Galectin-9 is
detected by immunohistochemistry using the 1G3 mab. A) Absence of galectin-9 staining on a section of a paraffin-embedded pellet of BL2 cells
(X200). B) Intense albeit heterogenous galectin-9 staining on a section of a paraffin-embedded pellet of REMB1 cells (X100). C) NPC tumor biopsy.
(Table 1, patient #2, undifferentiated non-keratinizing) (X100). Intense galectin-9 staining is seen in the nests of malignant cells which are clearly
separated from the abundant lymphoid stroma. In addition, a weaker staining is seen in a large number of stromal cells. D) NPC tumor biopsy
(Table 1, patient #10, undifferentiated non-keratinizing) (X100). Galectin-9 staining is only seen in spans of epithelial cells which are distinct from
the lymphoid stroma. E) NPC tumor biopsy (Table 1, patient #1, undifferentiated non-keratinizing) (X100). Malignant cells are intermingled with
infiltrating leucocytes. Galectin-9 is detected in both malignant and infiltrating cells. In contrast, it is completely undetectable in the non-
malignant epithelium. F) Oropharynx squamous cell carcinoma (Table 1, patient #13) (X100). Complete absence of galectin-9 staining in
malignant cells.
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Discussion
Galectin-9 has complex immunomodulatory properties
with action on effector cells of both innate and adap-
tative immunity. It induces secretion of pro-Th1
(interferon-gamma) and inflammatory cytokines by
monocytes and NK-cells whereas it has an inhibitory ef-
fect on NK-cell cytotoxicity [18,19]. On the other hand it
is inhibitory for mature CD4+ Th1 cells whereas it favors
expansion of regulatory T-cells [1,12]. Overall galectin-9
appears to have pro-inflammatory and immuno-
suppressive functions. This is consistent with its role of
facilitation for various types of viral infections in murine
experimental systems [4,6]. Out of seven monoclonal
antibodies directed to the c-terminus of galectin-9, 1G3
was the best suited for immunohistochemistry. The epi-
tope mapping and competition assay provide evidence
that its target epitope is included in the following amino-
acid sequence TPAIPPMMYPHPA (residues 210 to 222
of the long isoform). The ELISA capture assay demon-
strates that it cross-reacts with the murine galectin-9.
1G3 also reacts with murine galectin-9 analysed by west-
ern blotting (data not shown). This is not surprising be-
cause murine galectin-9 contains in its linker domain an
amino-acid sequence which is highly homologous to its
human target (residues 208 to 220 of murine galectin-9
long isoform, “TPGIPPVVYPTPA”). In contrast, 1G3
does not react with human galectin-1, 2, 3, 4, 8 and 10 in
the same assay.
Using 1G3 to analyse clinical specimens, we have con-
firmed that galectin-9 is abundant in two types of
human tissues infected by oncogenic viruses, nasopha-
ryngeal carcinoma and liver chronically infected by HCV
or HBV. Galectin-9 was detected in malignant cells from
all nasopharyngeal carcinoma specimens. Sporadic stain-
ing was also seen in some tumor infiltrating leucocytes.
These finding are consistent with our initial report on
galectin-9 in NPC [20]. However, in contrast with this
initial report, galectin-9 was rarely detected in non-
malignant mucosa. This is probably due to the fact that
the polyclonal antibody used for this previous study was
causing more background staining than the purified 1G3
monoclonal antibody. Galectin-9 nuclear staining was
observed at least in a fraction of the cells in all but one
NPC case. Nuclear distribution of galectin-9 has been
recently reported in a completely different setting, pre-
cisely in microglia/macrophages of active lesions of MS
stained with a rabbit polyclonal anti-galectin-9 [13]. In
contrast, in chronic inactive MS lesions, galectin-9 was
entirely localized in the cytoplasm. To our knowledge, a
specific role for nuclear galectin-9 has not been yet
described. Keeping in mind the immunosuppressive
functions of galectin-9, it will be interesting to know
whether relative galectin-9 abundance will be predictive
of NPC tumor response to various therapeutic modal-
ities especially adoptive immunotherapy [21,22].
Staining galectin-9 in liver specimens has resulted in
confirming results and some unexpected findings. First,
we have confirmed that galectin-9 is undetectable or at
very low abundance in non-infected liver parenchyma.
In contrast, it is detectable in HCV-infected liver tissue
Table 1 Detection of galectin-9 in biopsies from head and neck carcinomas
Patient Origin Gender/
Age
Tumor site/Histological Type Clinical
stage
Galectin-9 staining
Malignant
cells
Stroma
cells
Adjacent mucosa
(epithelium type)
1 Tunisia M/48 NPC/UNK* T4N3bM1 + + + - (malpighian)
2 Romania F/34 NPC/UNK T2bN0M0 + + + - (malpighian)
3 Cameroon M/62 NPC/UNK T4N2M0 + + - + (secretory)
4 France M/63 NPC/UNK T4N0Mx + + + n/a
5 France M/62 NPC/UNK T3N2M0 + + + n/a
6 Portugal F/84 NPC/UNK T4N2M0 + + + n/a
7 Algeria M/40 NPC/UNK T4N2M0 + + - + (malpighian)
8 Turkey M/57 NPC/UNK T1N0M0 + + + n/a
9 China F/31 NPC/UNK T4N0M0 + + - - (malpighian)
10 France M/48 NPC/UNK T1N2M0 + + - - (secretory)
11 France M/62 Tonsil/Infiltrating SCC** T2N1M0 + + - (malpighian)
12 France F/82 Tongue/Differentiated SCC T2N0M0 - + - (malpighian)
13 France M/64 Pelvi-lingual furrow/Differentiated SCC T2N1M0 - + - (malpighian)
* NPC/UNK : nasopharyngeal carcinoma/undifferentiated non-keratinizing, ** SCC : squamous cell carcinoma, ++ : intense and homogeneous galectin-9 staining,
+ : moderate or scattered galectin-9 staining, - : absence of galectin-9 staining, n/a : not applicable (no segment of non malignant mucosa observed in the tissue
section).
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sections. It is noteworthy that it is also detectable in liver
samples infected by HBV. In addition to Kupffer cells, it
seems to be often expressed by various types of inflam-
matory leucocytes. Surprisingly, it is also detected in a
large proportion of hepatocytes in all infected samples
under the form of small punctuations localized in the
cytoplasm and visible only at high magnification (X400).
This means that although the amount of galectin-9 per cell
is relatively low in hepatocytes, altogether these hepatocytes
probably represent a major source of galectin-9 for the
organisms of HCV- or HBV-infected individuals. These
observations raise a series of questions to be addressed in
future experiments. It will be interesting to know whether
the plasma concentration of galectin-9 is increased for
patients chronically infected by HBV as reported by us for
patients infected by HCV [12]. Another question will be to
determine to what extent the intensity of galectin-9 expres-
sion in chronically infected livers correlates with the sever-
ity of tissue lesions and the risk of hepatocarcinoma. One
may also wonder whether galectin-9 abundance in tissue
sections correlates with its concentration in peripheral
blood.
Figure 5 Detection of galectin-9 in liver tissue sections. A, B) Normal liver tissue next to an adenoma (Table 2, patient #8, X100 and X400
respectively). Complete absence of galectin-9 staining. C, D) HCV-related liver cirrhosis next to a carcinoma (Table 2, patient #2, X100 and X400
respectively). Prominent staining is visible in Kupffer cells which are characterized by a flat triangle shape and their close association with sinusoid
vessels. At high magnification, delicate, punctate staining is visible in a large number of hepatocytes (black arrows). E and F) HBV-related liver
cirrhosis next to a carcinoma. (Table 2, patient #5) Predominant staining in various types of leucocytes often with a round shape. At high
magnification, delicate punctate staining is visible in a large number of hepatocytes (black arrows).
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Conclusion
We report the performances of 1G3 a novel mab useful to
assess not only the abundance and tissue distribution of
galectin-9, but also its cytoplasmic and nuclear distribu-
tion. Future aims will be to investigate whether galectin-9
abundance in tissue sections is predictive of responses to
various tumor modalities, especially adoptive immuno-
therapy. Regarding chronic hepatitis B and C, it will be
useful to detemine whether galectin-9 abundance corre-
lates with disease severity and correlates with the risk of
hepatocarcinoma.
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